history of breast cancer icd-10

Release time ：Dec-18,2024

Breast cancer is historically coded as C50 in the ICD-10 classification system. This code encompasses malignant neoplasms of the breast, which include a variety of subtypes, each with distinct biological properties and therapeutic approaches. Generally, the diagnosis and treatment strategy for breast cancer are contingent upon the tumor's specific subtype, grade, stage, and the patient's unique circumstances.

The most prevalent subtypes of breast cancer are ductal carcinoma and lobular carcinoma. Ductal carcinoma arises from the ductal system of the breast, whereas lobular carcinoma originates from the milk-producing lobules. These two subtypes of breast cancer are often responsive to hormonal therapy, making it essential to determine whether the tumor cells express estrogen receptors (ER) and progesterone receptors (PR) to inform treatment strategies. Additionally, the presence or absence of the HER2/neu protein, which is overexpressed in some breast cancer cells, also influences treatment decisions.

Beyond these common subtypes, there are less frequent but more aggressive forms of breast cancer, such as inflammatory breast cancer and triple-negative breast cancer. Inflammatory breast cancer is marked by skin redness and thickening, whereas triple-negative breast cancer is characterized by the absence of ER, PR, and HER2 expression, rendering these tumors less susceptible to standard hormonal and targeted therapies and more challenging to treat.

For patients with a history of breast cancer, regular follow-ups and examinations are imperative for the early detection of recurrence or metastasis. Concurrently, patients should adhere to their physician's recommendations to maintain a healthy lifestyle, including maintaining an appropriate weight, a balanced diet, and regular physical activity, to mitigate the risk of disease recurrence. Throughout the treatment process, patients must strictly comply with their doctor's medication regimen and avoid self-adjusting dosages or discontinuing medication to prevent compromising treatment efficacy and increasing the risk of adverse effects.